Bubs share price tumbles 5% amid broker downgrade

Bubs shares are heading south on Tuesday…

| More on:
person holding hand to head in despair while holding a glass of milk with the other hand.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Bubs shares are giving back some of Monday's impressive gains
  • Its shares rocketed higher on news of a deal with the US Government for 1.25 million tins of infant formula
  • A leading broker has downgraded Bubs shares today largely on valuation grounds after the strong gain

The Bubs Australia Ltd (ASX: BUB) share price has run out of steam on Tuesday morning.

At the time of writing, the infant formula company's shares are down 5% to 64.5 cents.

Why is the Bubs share price sinking today?

There appear to be a couple of catalysts for the weakness in the Bubs share price on Tuesday.

The first is profit taking after a stellar gain on Monday following news that the company has struck a deal with the Biden Administration to supply 1.25 million tins of infant formula to help with shortages in the United States.

The market's reaction was so positive that the Bubs share price remains up 33% this week despite today's decline.

What else is weighing on its shares?

Also potentially weighing on the Bubs share price is a broker note out of Bell Potter this morning.

According to the note, the broker has downgraded the company's shares to a (speculative) hold rating with an improved price target of 75 cents.

Bell Potter was pleased with the aforementioned news but highlights that the US FDA's infant formula enforcement discretion policy (IFEDP) is only in place effect until November. As such, it is treating this development largely as a temporary sales boost. It said:

The IFEDP is only in effect until Nov'22 and in this light we have treated this largely as a temporary sales boost, with additional toddler formula sales thereafter.

Though, the broker does acknowledge that the announcement should boost brand awareness in the US, which is a market it believes could be very lucrative for Bubs. It explained:

At the very least the announcement de-risks near term sales forecasts for BUB, which are premised on execution against the Alpha Group equity linked distribution deal announced earlier in the year.

It could also be a viewed as a positive signal for BUB's achieving future USFDA approval for its infant products and enhanced brand awareness for its existing toddler products which are already distributed in the US. The upside potential in the US is high, particularly the organic grass fed IMF product, where we have estimated in the past a 2.0-4.5m pa tin opportunity for similar products.

However, due to the strong rise in the Bubs share price, the broker doesn't believe the risk/reward on offer is enough to maintain a buy rating.

It concludes:

This is a good announcement for BUB and at the least will likely result in increased US brand awareness while benefiting near term cashflows. BUB remains a high ceiling growth play in the IMF, however, in light of the recent share price gain we downgrade our rating from Buy, Speculative risk to Hold, Speculative risk.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BUBS AUST FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares.

Read more »

Two brokers analysing stocks.
Broker Notes

Goldman Sachs says this ASX 200 stock is a buy with 25%+ upside

Let's see why the broker is bullish on this name right now.

Read more »

Happy man holding Australian dollar notes, representing dividends.
Broker Notes

Why this cheap ASX All Ords stock could rise 50% and pay an 11% dividend yield

Goldman Sachs thinks that big returns could be coming for buyers of this stock.

Read more »

Woman using a pen on a digital stock market chart in an office.
Broker Notes

CSL stock: Buy, hold, or sell in 2025?

Let's see what analysts are saying about this blue chip giant at the start of the year.

Read more »

a woman holds a facebook like thumbs up sign high above her head. She has a very happy smile on her face.
Broker Notes

Goldman Sachs says this ASX 200 stock is a top buy in January

The broker is forecasting some big returns for investors this year.

Read more »

A man working in the stock exchange.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys right now.

Read more »

A group of businesspeople clapping.
Broker Notes

2 of the best ASX 200 shares to buy in the Asia-Pacific

Goldman Sachs is speaking very highly about these stocks this month.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Broker Notes

4 ASX 200 shares just upgraded for 2025 by top brokers

Leading brokers are forecasting strong performance in 2025 from these four ASX 200 companies.

Read more »